SCHEMBL5745579

SCHEMBL5745579

C=CCc1cnc2c(c1)C(=O)N(C)c1ccc(C)nc1N2CC

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 5/20 0.49
CYP2C9 P11712 5/20 0.49
CYP2C19 P33261 5/20 0.49
CYP1A2 P05177 3/20 0.49
CYP2D6 P10635 2/20 0.36
LRRK2 Q5S007 2/20 0.31
DCLK1 O15075 1/20 0.31
MAPK7 Q13164 1/20 0.31
NPC1 O15118 2/20 0.31
RAB9A P51151 2/20 0.31
KMT2A Q03164 1/20 0.31
AURKA O14965 2/20 0.31
AURKB Q96GD4 2/20 0.31
PIK3CD O00329 1/20 0.31
PIK3C2G O75747 1/20 0.31
PIK3CG P48736 1/20 0.31
BRD4 O60885 2/20 0.31
PLK4 O00444 1/20 0.30
AURKC Q9UQB9 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4680335 0.88 CYP3A4 (0.59) CYP3A4CYP2C9CYP2C19CYP1A2CYP2D6
SCHEMBL4033760 0.88 CYP3A4 (0.47) CYP3A4CYP2C9CYP2C19CYP1A2CYP2D6
SCHEMBL5743651 0.86 CYP3A4 (0.54) CYP3A4CYP2C9CYP2C19CYP1A2CYP2D6
SCHEMBL5745475 0.86 CYP3A4 (0.47) CYP3A4CYP2C9CYP2C19CYP1A2CYP2D6
SCHEMBL4033199 0.84 CYP3A4 (0.58) CYP3A4CYP2C9CYP2C19CYP1A2BRD4
SCHEMBL5746037 0.81 CYP3A4 (0.44) CYP3A4CYP2C9CYP2C19CYP1A2CYP2D6
SCHEMBL6959247 0.76 CYP3A4 (0.48) CYP3A4CYP2C9CYP2C19CYP1A2CYP2D6
SCHEMBL6953361 0.75 CYP3A4 (0.50) CYP3A4CYP2C9CYP2C19CYP1A2CYP2D6
SCHEMBL6959756 0.75 CYP3A4 (0.48) CYP3A4CYP2C9CYP2C19CYP1A2CYP2D6
SCHEMBL5744358 0.74 CYP3A4 (0.65) CYP3A4CYP2C9CYP2C19CYP1A2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1655300-A1 Non-nucleoside reverse transcriptase inhibitors BOEHRINGER INGELHEIM (CANADA) LTD. (CA) 2006-05-10 EP disclosed
EP-1294720-B1 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS BOEHRINGER INGELHEIM CA LTD (CA) 2006-04-05 EP disclosed
US-6420359-B1 5,11-Dihydro-11-ethyl-5-methyl-8-(2-((1-oxido-4-quinolinyl)oxy)ethyl)-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one for example; antiviral agents for HIV infection BOEHRINGER INGELHEIM (CANADA) LTD. (CA) 2002-07-16 US disclosed
US-20020028807-A1 Non-nucleoside reverse transcriptase inhibitors BOEHRINGER INGELHEIM (CANADA) LTD. (CA) 2002-03-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020028807-A1 Non-nucleoside reverse transcriptase inhibitors REV1, POLR2H, POLR2E CYP3A4 560/4885CYP2C9 1933/4885CYP2C19 1639/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.